Elan

Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?

Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?

Forbes

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales

Yahoo/AP

Elan considered buying Royalty before becoming its target

Elan considered buying Royalty before becoming its target

Reuters

Royalty Pharma stands by reduced Elan bid

Royalty Pharma stands by reduced Elan bid

Reuters

Elan sees sales of prized Tysabri drug rise sharply

Elan sees sales of prized Tysabri drug rise sharply

Reuters

Elan rejects Royalty bid as grossly undervaluing its prospects

Elan rejects Royalty bid as grossly undervaluing its prospects

Reuters

Elan buyback priced at $11.25 reduces Royalty bid

Elan buyback priced at $11.25 reduces Royalty bid

Reuters

Royalty Pharma sweetens offer for Elan

Royalty Pharma sweetens offer for Elan

Reuters

Elan shareholders approve buyback as Royalty fight heats up

Elan shareholders approve buyback as Royalty fight heats up

Reuters

Elan completes sale of Tysabri stake to Biogen

Elan completes sale of Tysabri stake to Biogen

Reuters